Effects of ferric citrate hydrate in patients with chronic kidney disease and heart failure: subgroup analysis of a long-term, real-world, post-marketing surveillance study
Abstract Background Iron deficiency is widely present in patients with heart failure (HF) and is associated with an increased risk of mortality and poor clinical outcomes regardless of anemia. HF is highly prevalent in patients with chronic kidney disease (CKD). However, existing oral iron preparati...
Main Authors: | Kyoko Ito, Kenjiro Murakami, Ryoichi Yamada, Hiroyuki Susai, Noriaki Nishino |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-12-01
|
Series: | Renal Replacement Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1186/s41100-022-00454-z |
Similar Items
-
Ferritin Elevation and Improved Responsiveness to Erythropoiesis-Stimulating Agents in Patients on Ferric Citrate Hydrate
by: Keitaro Yokoyama, et al.
Published: (2017-05-01) -
Long-term iron accumulation in dialysis patients treated with ferric citrate hydrate: a single-center, 80-week retrospective study in Japan
by: Maki Hiratsuka, et al.
Published: (2017-09-01) -
Oral Ferric Citrate Hydrate Associated With Less Oxidative Stress Than Intravenous Saccharated Ferric Oxide
by: Masaaki Nakayama, et al.
Published: (2018-03-01) -
Oral Iron Absorption of Ferric Citrate Hydrate and Hepcidin-25 in Hemodialysis Patients: A Prospective, Multicenter, Observational Riona-Oral Iron Absorption Trial
by: Naohisa Tomosugi, et al.
Published: (2023-09-01) -
Efficacy of oral ferric citrate hydrate treatment for anemia caused by niraparib: a case report
by: Hiroshi Kobayashi, et al.
Published: (2022-11-01)